City

Clinical trials near Krakow, Poland

Active studies with a listed research site in Krakow, Poland.

12active studies

11recruiting now

20countries represented

136largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, SemaglutideTreatment

Australia, Bulgaria59 locations

KaileraSponsor

Updated 2026-09-01 · NCT07284979See eligibility →

Recruiting nowPhase 3

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Belgium, Brazil117 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672549See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, Bulgaria81 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT07509307See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Czechia, Germany136 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743450See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Canada, Czechia120 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743463See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowPhase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA)Condition

NNC0487-0111, Placebo (matched to NNC0487-0111 )Treatment

Australia, Bulgaria82 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07481630See eligibility →

Recruiting nowNot applicable

Genetic, Microbiological and Behavioral Factors in Obesity

Obesity & Overweight, ObesityCondition

genetic polymorphism, gut microbiomeTreatment

Poland2 locations

Jan Kochanowski UniversitySponsor

Updated 2026-06-16 · NCT07650149See eligibility →

Recruiting nowNot applicable

Comparison of Nissen-Sleeve and Gastric Bypass for GERD in Obese Patients

Gastro Esophageal Reflux, Severe ObesityCondition

Nissen-Sleeve Gastrectomy (N-SG), Roux-en-Y Gastric Bypass (RYGB)Treatment

Poland1 locations

Jagiellonian UniversitySponsor

Updated 2025-09-05 · NCT07158008See eligibility →

Active, not recruitingPhase 2

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Obesity, OverweightCondition

RO7204239, RO7204239 Matching PlaceboTreatment

Poland, Spain35 locations

Hoffmann-La RocheSponsor

Updated 2026-08-11 · NCT06965413See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Krakow, Poland

Current studies

Related cities